HALO Halozyme Therapeutics Inc
$120.83
▼ 0.6%Updated Oct 16, 2:25 PM ET
Report Card
HALO at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
16.0%
Interest Coverage
25x
Current Ratio
2.71x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
Halozyme Therapeutics Inc (HALO) is a NASDAQ-listed company in the Biotechnology industry, within the Health Care sector.
In its latest reported year it generated about $1.40B in revenue and $316.89M in net profit.
Our model hasn't rated HALO yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (9 years of history).
Profit margins and economic moats, explainedSome durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
42.9% average over the last 3 years
±36.8 pts around 25.6% across 9 years
grew in 7 of the last 8 year-over-year periods
positive in 7 of 9 years
16.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Revenue Growth
4Y CAGR
33.2%
Revenue moved from $316.61M in 2017 to $1.40B in 2025, a 20.4% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
—
Operating Margin
33.6%
Net Margin
22.7%
ROE
—
Debt Analysis
Total Debt
$2.14B
Net Debt
$1.98B
Net Debt / EBITDA
4.22x
Debt / Equity
—
Leverage: debt-to-equity is n/a, and operating profit covers interest about 25.0x, with a current ratio of 2.7x. Detailed balance-sheet leverage is limited for this name. It carries roughly $2.14B of total debt against $163.14M of cash.
Cash Flow Analysis
Operating CF
$651.56M
Free Cash Flow
$644.59M
FCF Margin
46.2%
In the latest year Halozyme Therapeutics Inc produced about $651.56M of operating cash flow and $644.59M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
HALO trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$97.51
Current price
$120.83
Starting FCF (latest 10-K)
$644.59M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where HALO sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How HALO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
HALO doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$49.90 – $83.17
vs. $120.83 today · implied CAGR -16% – -7%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.51B | $1.63B | $1.76B | $1.90B | $2.05B |
| Net income | $346.92M | $374.67M | $404.65M | $437.02M | $471.98M |
| EPS | $3.06 | $3.30 | $3.57 | $3.85 | $4.16 |
| Share price (low) | $36.68 | $39.61 | $42.78 | $46.21 | $49.90 |
| Share price (high) | $61.13 | $66.02 | $71.30 | $77.01 | $83.17 |
| CAGR (low–high) | -70% / -49% | -43% / -26% | -29% / -16% | -21% / -11% | -16% / -7% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Analyst Ratings
What 16 Wall Street analysts covering HALO recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+13 pts of buy ratings).
Latest SEC Filings
HALO's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
HALO — frequently asked questions
Is HALO a good stock to buy?
We don't give buy or sell advice. Review Halozyme Therapeutics Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does HALO's data come from?
Live price data plus the annual financials in Halozyme Therapeutics Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for HALO calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this HALO analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell HALO. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.